Current and emerging therapies in primary myelofibrosis

Sabarish Ayyappan, Murali Janakiram, Radha Raghupathy

Research output: Contribution to journalArticle

Abstract

Primary myelofibrosis is a clonal hematopoietic disorder characterized by ineffective hematopoiesis and progressive bone marrow fibrosis. Patients with high risk myelofibrosis as determined by their advanced age, degree of anemia, leukocytosis, constitutional symptoms and high percentage of circulating blasts have a very short median survival of 2 years. In addition quality of life is significantly compromised due to cytokine induced constitutional symptoms, frequent transfusion for cytopenias and bulky splenomegaly. Progression to myelogenous leukemia occurs in about 20% of patients within 10 years of diagnosis and is often fatal. Allogeneic hematopoietic transplantation is the only curative therapy but is limited by patient eligibility, transplant related mortality and graft versus host disease. Androgens, erythropoietin analogues, hydroxyurea, alkylators and spleen directed therapies have all been used with limited efficacy and no curative potential. The discovery of mutations in the hematopoietic progenitors of patients with myelofibrosis, including the JAK2 V617F mutation and others has greatly improved our understanding of the disease and facilitated development of newer targeted therapies. Our article will review new discoveries in the pathogenesis of myelofibrosis and focus on emerging targeted treatments. These novel therapies including oral JAK2 inhibitors, immunomodulators, as well as inhibitors of HDAC and mTOR, in isolation and in combination are likely to improve outcomes in management of this disease.

Original languageEnglish (US)
Pages (from-to)6-20
Number of pages15
JournalCardiovascular and Hematological Disorders - Drug Targets
Volume12
Issue number1
DOIs
StatePublished - 2012
Externally publishedYes

Fingerprint

Primary Myelofibrosis
Testosterone Congeners
Therapeutics
Mutation
Histone Deacetylase Inhibitors
Myeloid Leukemia
Hydroxyurea
Alkylating Agents
Splenomegaly
Homologous Transplantation
Leukocytosis
Hematopoiesis
Immunologic Factors
Graft vs Host Disease
Disease Management
Erythropoietin
Anemia
Spleen
Quality of Life
Cytokines

Keywords

  • HDAC inhibitors
  • Hypomethylating agents
  • Interferon α
  • JAK2
  • mTOR inhibitors
  • Myelofibrosis
  • Targeted therapies

ASJC Scopus subject areas

  • Molecular Medicine
  • Cardiology and Cardiovascular Medicine
  • Hematology
  • Pharmacology

Cite this

Current and emerging therapies in primary myelofibrosis. / Ayyappan, Sabarish; Janakiram, Murali; Raghupathy, Radha.

In: Cardiovascular and Hematological Disorders - Drug Targets, Vol. 12, No. 1, 2012, p. 6-20.

Research output: Contribution to journalArticle

Ayyappan, Sabarish ; Janakiram, Murali ; Raghupathy, Radha. / Current and emerging therapies in primary myelofibrosis. In: Cardiovascular and Hematological Disorders - Drug Targets. 2012 ; Vol. 12, No. 1. pp. 6-20.
@article{db3335b460f04a95b5de2ad0de5a2c6e,
title = "Current and emerging therapies in primary myelofibrosis",
abstract = "Primary myelofibrosis is a clonal hematopoietic disorder characterized by ineffective hematopoiesis and progressive bone marrow fibrosis. Patients with high risk myelofibrosis as determined by their advanced age, degree of anemia, leukocytosis, constitutional symptoms and high percentage of circulating blasts have a very short median survival of 2 years. In addition quality of life is significantly compromised due to cytokine induced constitutional symptoms, frequent transfusion for cytopenias and bulky splenomegaly. Progression to myelogenous leukemia occurs in about 20{\%} of patients within 10 years of diagnosis and is often fatal. Allogeneic hematopoietic transplantation is the only curative therapy but is limited by patient eligibility, transplant related mortality and graft versus host disease. Androgens, erythropoietin analogues, hydroxyurea, alkylators and spleen directed therapies have all been used with limited efficacy and no curative potential. The discovery of mutations in the hematopoietic progenitors of patients with myelofibrosis, including the JAK2 V617F mutation and others has greatly improved our understanding of the disease and facilitated development of newer targeted therapies. Our article will review new discoveries in the pathogenesis of myelofibrosis and focus on emerging targeted treatments. These novel therapies including oral JAK2 inhibitors, immunomodulators, as well as inhibitors of HDAC and mTOR, in isolation and in combination are likely to improve outcomes in management of this disease.",
keywords = "HDAC inhibitors, Hypomethylating agents, Interferon α, JAK2, mTOR inhibitors, Myelofibrosis, Targeted therapies",
author = "Sabarish Ayyappan and Murali Janakiram and Radha Raghupathy",
year = "2012",
doi = "10.2174/187152912801823174",
language = "English (US)",
volume = "12",
pages = "6--20",
journal = "Cardiovascular and Hematological Disorders - Drug Targets",
issn = "1871-529X",
publisher = "Bentham Science Publishers B.V.",
number = "1",

}

TY - JOUR

T1 - Current and emerging therapies in primary myelofibrosis

AU - Ayyappan, Sabarish

AU - Janakiram, Murali

AU - Raghupathy, Radha

PY - 2012

Y1 - 2012

N2 - Primary myelofibrosis is a clonal hematopoietic disorder characterized by ineffective hematopoiesis and progressive bone marrow fibrosis. Patients with high risk myelofibrosis as determined by their advanced age, degree of anemia, leukocytosis, constitutional symptoms and high percentage of circulating blasts have a very short median survival of 2 years. In addition quality of life is significantly compromised due to cytokine induced constitutional symptoms, frequent transfusion for cytopenias and bulky splenomegaly. Progression to myelogenous leukemia occurs in about 20% of patients within 10 years of diagnosis and is often fatal. Allogeneic hematopoietic transplantation is the only curative therapy but is limited by patient eligibility, transplant related mortality and graft versus host disease. Androgens, erythropoietin analogues, hydroxyurea, alkylators and spleen directed therapies have all been used with limited efficacy and no curative potential. The discovery of mutations in the hematopoietic progenitors of patients with myelofibrosis, including the JAK2 V617F mutation and others has greatly improved our understanding of the disease and facilitated development of newer targeted therapies. Our article will review new discoveries in the pathogenesis of myelofibrosis and focus on emerging targeted treatments. These novel therapies including oral JAK2 inhibitors, immunomodulators, as well as inhibitors of HDAC and mTOR, in isolation and in combination are likely to improve outcomes in management of this disease.

AB - Primary myelofibrosis is a clonal hematopoietic disorder characterized by ineffective hematopoiesis and progressive bone marrow fibrosis. Patients with high risk myelofibrosis as determined by their advanced age, degree of anemia, leukocytosis, constitutional symptoms and high percentage of circulating blasts have a very short median survival of 2 years. In addition quality of life is significantly compromised due to cytokine induced constitutional symptoms, frequent transfusion for cytopenias and bulky splenomegaly. Progression to myelogenous leukemia occurs in about 20% of patients within 10 years of diagnosis and is often fatal. Allogeneic hematopoietic transplantation is the only curative therapy but is limited by patient eligibility, transplant related mortality and graft versus host disease. Androgens, erythropoietin analogues, hydroxyurea, alkylators and spleen directed therapies have all been used with limited efficacy and no curative potential. The discovery of mutations in the hematopoietic progenitors of patients with myelofibrosis, including the JAK2 V617F mutation and others has greatly improved our understanding of the disease and facilitated development of newer targeted therapies. Our article will review new discoveries in the pathogenesis of myelofibrosis and focus on emerging targeted treatments. These novel therapies including oral JAK2 inhibitors, immunomodulators, as well as inhibitors of HDAC and mTOR, in isolation and in combination are likely to improve outcomes in management of this disease.

KW - HDAC inhibitors

KW - Hypomethylating agents

KW - Interferon α

KW - JAK2

KW - mTOR inhibitors

KW - Myelofibrosis

KW - Targeted therapies

UR - http://www.scopus.com/inward/record.url?scp=84867553142&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84867553142&partnerID=8YFLogxK

U2 - 10.2174/187152912801823174

DO - 10.2174/187152912801823174

M3 - Article

C2 - 22746348

AN - SCOPUS:84867553142

VL - 12

SP - 6

EP - 20

JO - Cardiovascular and Hematological Disorders - Drug Targets

JF - Cardiovascular and Hematological Disorders - Drug Targets

SN - 1871-529X

IS - 1

ER -